Combined Afirma Genomic Sequencing Classifier and TERT promoter mutation detection in molecular assessment of Bethesda III-VI thyroid nodules

Cancer Cytopathol. 2023 Oct;131(10):609-613. doi: 10.1002/cncy.22744. Epub 2023 Aug 6.

¹ Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
² Department of Medical Affairs, Veracyte, South San Francisco, California, USA.
³ Department of Research and Development, Veracyte, South San Francisco, California, USA.
⁴ Department of Marketing, Veracyte, South San Francisco, California, USA.
⁵ Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

No abstract available

Keywords: Afirma; TERT; diagnosis; molecular diagnostics; prognosis; targeted therapy; thyroid nodules.

MeSH terms